ADVERTISEMENT
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Related topics
PRESS RELEASE: Paid content from Globe Newswire
Press release content from Globe Newswire. The AP news staff was not involved in its creation.

Tiziana Life Sciences plc: PDMR Dealing

September 28, 2021 GMT

LONDON and NEW YORK, Sept. 28, 2021 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (Nasdaq: TLSA / LSE: TILS) (“Tiziana” or the “Company”), a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases, today announces that it has been notified that Panetta Partners Limited, an entity in which Gabriele Cerrone, the Executive Chairman has a beneficial interest, purchased 100,000 ordinary shares of 3p each in the market at a price of 52p per share.

The acquisition takes Mr Cerrone’s interests from 34.078% to 34.129% (within the 1% incremental threshold under Note 11 to Rule 9 of the UK Takeover Code).

1.Details of PDMR / person closely associated
a)NameGabriele Cerrone
2.Reason for the notification
a)Position / statusChairman
b)Initial notification /amendmentInitial notification
3.Details of the issuer
a)NameTiziana Life Sciences plc
b)LEI213800CED47HI8PIOB36
4.Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type  of transaction; (iii) each date; and (iv) each place where transactions have  been conducted
a)Description of the financial instrumentOrdinary Shares of 3p each
b)Identification code of the Financial InstrumentISIN for Tiziana Life Sciences plc: GB00BKWNZY55
c)Nature of the transactionMarket Purchase
d)Price(s) and volume(s) 52p

100,000
f)Date of the transaction27 September 2021
g)Place of the transactionXLON  
ADVERTISEMENT
ADVERTISEMENT

About Tiziana Life Sciences

Tiziana Life Sciences plc is a dual listed (NASDAQ:TLSA, UK LSE: TILS) biotechnology company that focuses on the discovery and development of novel molecules to treat human diseases in oncology, inflammation and infectious diseases. In addition to Milciclib, the Company will be shortly initiating Phase 2 studies with orally administered Foralumab for Crohn’s Disease and nasally administered Foralumab for progressive multiple sclerosis. Foralumab is the only fully human anti-CD3 monoclonal antibody (“mAb”) in clinical development in the world. This Phase 2 compound has potential application in a wide range of autoimmune and inflammatory diseases, such as Crohn’s Disease, multiple sclerosis, type-1 diabetes (“T1D”), inflammatory bowel disease (“IBD”), psoriasis and rheumatoid arthritis, where modulation of a T-cell response is desirable. The Company is accelerating development of anti-Interleukin 6 receptor (“IL6R”) mAb, a fully human monoclonal antibody for treatment of IL6-induced inflammation, especially for treatment of COVID-19 patients.

For further enquiries:

Tiziana Life Sciences plc+44 (0)20 7495 2379  
Gabriele Cerrone, Chairman, and founder 
   
United States:  
Investors:  
Dave Gentry, CEO  
RedChip Companies Inc.  
407-491-4498  
dave@redchip.com